D-0631-2020 Class II Terminated

Recalled by American Health Packaging — Columbus, OH

FDA drug recall D-0631-2020 was initiated by American Health Packaging on Nov 1, 2019 and is designated Class II. Reason for recall: CGMP Deviations: Presence of NDMA impurity detected in product. The recall status is terminated (terminated Aug 3, 2022). Affected quantity: 1,692 cases of 40 and 50 cups.

Recall details

Product Type
Drugs
Report Date
Jan 8, 2020
Initiation Date
Nov 1, 2019
Termination Date
Aug 3, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,692 cases of 40 and 50 cups

Product description

Ranitidine Syrup (Ranitidine Oral Solution USP), 15 mg/mL, 150 mg/10 mL per cup, Rx Only, Distributed by: American Health Packaging, Columbus, Ohio. (a) Case of 50 cups (NDC 60687-260-69) (b) Case of 40 cups (NDC 60687-260-23 (c) Unit Dose Cup (NDC 60687-260-69)

Reason for recall

CGMP Deviations: Presence of NDMA impurity detected in product.

Distribution pattern

Nationwide USA

Code information

[Case of 40] Lots 183723, 184278, exp 10/31/2020; Lot 187652, exp 05/31/2021; [Case of 50] Lot 177874, exp 01/31/ 2020; Lot 178413, exp 02/29/ 2020; Lot 183449, exp 10/31/2020; Lot 184445, exp 12/31/ 2020; Lot 186563, exp 03/31/ 2021; Lot 187691, exp 05/31/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0631-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0631-2020. Report a data issue: hello@regdatalab.com.